The investigators conduct the clinical randomized controlled trial to evaluate the superiority of extended pancreatic neck transection during laparoscopic pancreaticoduodenectomy (LPD). The participants in the study group obtain extended pancreatic neck transection during LPD, while participants in the control group conventional pancreatic neck transection. The purposes of this study include: 1.Primary objective: To compare the incidence of clinically relevant pancreatic fistula (grades B-C according International Study Group on Pancreatic Surgery) between the study group and the control group. 2.Secondary objective: To compare the incidence of postoperative morbidity (Clavien-Dindo score ≥3)between the two groups. To compare the location of pancreatic duct and the surgical performance of pancreaticojejunostomy between the two groups.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
154
Transect the pancreatic neck at ≥5mm and ≤10mm beyond the left side of the portal vein.
West China Hospital of Sichuan University
Chengdu, Sichuan, China
the incidence of clinically relevant pancreatic fistula
the incidence of the clinically relevant pancreatic fistula according the International Study Group of Pancreatic Surgery's definition and grading
Time frame: 3 months postoperatively
location of the pancreatic duct in the pancreatic transverse section
Before performing the pancreaticojejunostomy, place the pancreatic transverse section in the central position of the lens. Measure the anterior-posterior diameter of the pancreas and the distance of the pancreatic duct from the back of the pancreas. The location of the pancreatic duct in the pancreatic transverse section is equal to the ratio of the distance of the pancreatic duct from the back of the pancreas to the anterior-posterior diameter of the pancreas.
Time frame: intraoperatively
surgical performance of pancreaticojejunostomy
the duration of pancreaticojejunostomy
Time frame: intraoperatively
postoperative morbidity
postoperative morbidity (Clavien-Dindo score ≥3)within 3 months postoperatively
Time frame: 3 months postoperatively
postoperative mortality
mortality within 3 months postoperatively
Time frame: 3 months postoperatively
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.